Literature DB >> 9010022

Mutations at codon 974 of the DPYD gene are a rare event.

S A Ridge1, O Brown, J McMurrough, P Fernandez-Salguero, W E Evans, F J Gonzalez, H L McLeod.   

Abstract

A mutation at codon 974 of the dihydropyrimidine dehydrogenase (DPD) gene was previously described in a cancer patient with undetectable DPD enzyme activity who experienced severe toxicity when treated with 5-fluorouracil. We have studied the frequency of this mutation in 29 Scottish subjects with low DPD enzyme activity and in 274 American subjects. We detected no mutations in the 606 alleles studied and conclude that mutations at codon 974 are a rare event.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9010022      PMCID: PMC2063286          DOI: 10.1038/bjc.1997.29

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome.

Authors:  B E Harris; J T Carpenter; R B Diasio
Journal:  Cancer       Date:  1991-08-01       Impact factor: 6.860

Review 2.  Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency.

Authors:  F J Gonzalez; P Fernandez-Salguero
Journal:  Trends Pharmacol Sci       Date:  1995-10       Impact factor: 14.819

Review 3.  Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency.

Authors:  P Houyau; C Gay; E Chatelut; P Canal; H Roché; G Milano
Journal:  J Natl Cancer Inst       Date:  1993-10-06       Impact factor: 13.506

Review 4.  Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy.

Authors:  G Milano; M C Etienne
Journal:  Pharmacogenetics       Date:  1994-12

5.  Thiopurine methyltransferase activity in American white subjects and black subjects.

Authors:  H L McLeod; J S Lin; E P Scott; C H Pui; W E Evans
Journal:  Clin Pharmacol Ther       Date:  1994-01       Impact factor: 6.875

6.  Population study of dihydropyrimidine dehydrogenase in cancer patients.

Authors:  M C Etienne; J L Lagrange; O Dassonville; R Fleming; A Thyss; N Renée; M Schneider; F Demard; G Milano
Journal:  J Clin Oncol       Date:  1994-11       Impact factor: 44.544

7.  Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.

Authors:  Z Lu; R Zhang; R B Diasio
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

8.  Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea.

Authors:  R Meinsma; P Fernandez-Salguero; A B Van Kuilenburg; A H Van Gennip; F J Gonzalez
Journal:  DNA Cell Biol       Date:  1995-01       Impact factor: 3.311

9.  Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency.

Authors:  C H Takimoto; Z H Lu; R Zhang; M D Liang; L V Larson; L R Cantilena; J L Grem; C J Allegra; R B Diasio; E Chu
Journal:  Clin Cancer Res       Date:  1996-03       Impact factor: 12.531

10.  Enzymes of uracil catabolism in normal and neoplastic human tissues.

Authors:  F N Naguib; M H el Kouni; S Cha
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

View more
  3 in total

1.  Dihydropyrimidine dehydrogenase deficiency: a novel mutation and expression of missense mutations in E. coli.

Authors:  P Vreken; A B van Kuilenburg; R Meinsma; F A Beemer; M Duran; A H van Gennip
Journal:  J Inherit Metab Dis       Date:  1998-06       Impact factor: 4.982

2.  Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil.

Authors:  D Dobritzsch; G Schneider; K D Schnackerz; Y Lindqvist
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

3.  Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.

Authors:  J Gao; Q He; D Hua; Y Mao; Y Li; L Shen
Journal:  Clin Transl Oncol       Date:  2012-12-21       Impact factor: 3.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.